RAD51 as a potential biomarker and therapeutic target for pancreatic cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1816, Issue 2, 2011, Pages 209-218

  Nagathihalli, Nagaraj S ^a   Nagaraju, Ganesh ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Biomarker; DNA repair; Drug resistance; Genome instability; Pancreatic cancer; RAD51

Indexed keywords

BIOLOGICAL MARKER; CHLORMETHINE; CISPLATIN; DASATINIB; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IMATINIB; LAPATINIB; METHOTREXATE; MICRORNA; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; RAD51 PROTEIN; SMALL INTERFERING RNA; VERAPAMIL; VINCRISTINE;

CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; DRUG MECHANISM; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; RAD51 RECOMBINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 80051576726     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.07.004     Document Type: Review

References (136)

1. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 2001, 27:247-254.
2. O'Driscoll M., Jeggo P.A. The role of double-strand break repair - insights from human genetics. Nat. Rev. Genet. 2006, 7:45-54.
3. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Orntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
4. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
5. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
6. Wyman C., Kanaar R. DNA double-strand break repair: all's well that ends well. Annu. Rev. Genet. 2006, 40:363-383.
7. Heyer W.D., Ehmsen K.T., Liu J. Regulation of homologous recombination in eukaryotes. Annu. Rev. Genet. 2010, 44:113-139.
8. Takata M., Sasaki M.S., Sonoda E., Morrison C., Hashimoto M., Utsumi H., Yamaguchi-Iwai Y., Shinohara A., Takeda S. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 1998, 17:5497-5508.
9. Johnson R.D., Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 2000, 19:3398-3407.
10. Branzei D., Foiani M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 2008, 9:297-308.
11. Moynahan M.E., Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol 2010, 11:196-207.
12. Nagaraju G., Scully R. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA Repair (Amst) 2007, 6:1018-1031.
13. Sung P., Klein H. Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol 2006, 7:739-750.
14. Bishop A.J., Schiestl R.H. Role of homologous recombination in carcinogenesis. Exp. Mol. Pathol. 2003, 74:94-105.
15. Richardson C., Moynahan M.E., Jasin M. Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev 1998, 12:3831-3842.
16. Stark J.M., Jasin M. Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. Mol. Cell. Biol. 2003, 23:733-743.
17. Moynahan M.E., Jasin M. Loss of heterozygosity induced by a chromosomal double-strand break. Proc Natl Acad Sci U S A 1997, 94:8988-8993.
18. Richardson C., Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000, 405:697-700.
19. Baumann P., Benson F.E., West S.C. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996, 87:757-766.
20. Gupta R.C., Bazemore L.R., Golub E.I., Radding C.M. Activities of human recombination protein Rad51. Proc Natl Acad Sci U S A 1997, 94:463-468.
21. Sung P., Robberson D.L. DNA strand exchange mediated by a RAD51-ssDNA nucleoprotein filament with polarity opposite to that of RecA. Cell 1995, 82:453-461.
22. Ogawa T., Yu X., Shinohara A., Egelman E.H. Similarity of the yeast RAD51 filament to the bacterial RecA filament. Science 1993, 259:1896-1899.
23. Baumann P., West S.C. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem. Sci. 1998, 23:247-251.
24. West S.C. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003, 4:435-445.
25. Bianco P.R., Tracy R.B., Kowalczykowski S.C. DNA strand exchange proteins: a biochemical and physical comparison. Front. Biosci. 1998, 3:D570-603.
26. Chen F., Nastasi A., Shen Z., Brenneman M., Crissman H., Chen D.J. Cell cycle-dependent protein expression of mammalian homologs of yeast DNA double-strand break repair genes Rad51 and Rad52. Mutat. Res. 1997, 384:205-211.
27. Yamamoto A., Taki T., Yagi H., Habu T., Yoshida K., Yoshimura Y., Yamamoto K., Matsushiro A., Nishimune Y., Morita T. Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol. Gen. Genet. 1996, 251:1-12.
28. Shrivastav M., De Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008, 18:134-147.
29. San Filippo J., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem. 2008, 77:229-257.
30. Paques F., Haber J.E. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 1999, 63:349-404.
31. Symington L.S. Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair. Microbiol. Mol. Biol. Rev. 2002, 66:630-670. (table of contents).
32. Tsuzuki T., Fujii Y., Sakumi K., Tominaga Y., Nakao K., Sekiguchi M., Matsushiro A., Yoshimura Y. MoritaT, targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci U S A 1996, 93:6236-6240.
33. Richardson C. RAD51, genomic stability, and tumorigenesis. Cancer Lett. 2005, 218:127-139.
34. Klein H.L. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst) 2008, 7:686-693.
35. Henning W., Sturzbecher H.W. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003, 193:91-109.
36. Kolodner R.D., Putnam C.D., Myung K. Maintenance of genome stability in Saccharomyces cerevisiae. Science 2002, 297:552-557.
37. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
38. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
39. Castellanos E.H., Cardin D.B., Berlin J.D. Treatment of early-stage pancreatic cancer. Oncology (Williston Park) 2011, 25:182-189.
40. Koorstra J.B., Hustinx S.R., Offerhaus G.J., Maitra A. Pancreatic carcinogenesis. Pancreatology 2008, 8:110-125.
41. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2002, 2:897-909.
42. Furukawa T. Pancreatic carcinogenesis and progression. Pancreas 2008, 37:111.
43. Hilgers W., Kern S.E. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 1999, 26:1-12.
44. Korc M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998, 7:25-41.
45. Goggins M., Hruban R.H., Kern S.E. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am. J. Pathol. 2000, 156:1767-1771.
46. Wilentz R.E., Goggins M., Redston M., Marcus V.A., Adsay N.V., Sohn T.A., Kadkol S.S., Yeo C.J., Choti M., Zahurak M., Johnson K., Tascilar M., Offerhaus G.J., Hruban R.H., Kern S.E. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am. J. Pathol. 2000, 156:1641-1651.
47. Maacke H., Jost K., Opitz S., Miska S., Yuan Y., Hasselbach L., Luttges J., Kalthoff H., Sturzbecher H.W. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000, 19:2791-2795.
48. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
49. Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., Misek D.E., Kuick R., Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63:2649-2657.
50. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
51. Saluja A.K., Lerch M.M., Phillips P.A., Dudeja V. Why does pancreatic overstimulation cause pancreatitis?. Annu. Rev. Physiol. 2007, 69:249-269.
52. Maacke H., Hundertmark C., Miska S., Voss S., Kalthoff H., Sturzbecher H.W. Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J. Cancer Res. Clin. 2002, 128:219-222.
53. Han H., Bearss D.J., Browne L.W., Calaluce R., Nagle R.B., Von Hoff D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 2002, 62:2890-2896.
54. Raderschall E., Stout K., Freier S., Suckow V., Schweiger S., Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002, 62:219-225.
55. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396:643-649.
56. Chen J.M., Cooper D.N., Chuzhanova N., Ferec C., Patrinos G.P. Gene conversion: mechanisms, evolution and human disease. Nat. Rev. Genet. 2007, 8:762-775.
57. Purandare S.M., Patel P.I. Recombination hot spots and human disease. Genome Res. 1997, 7:773-786.
58. Winter J.M., Maitra A., Yeo C.J. Genetics and pathology of pancreatic cancer. HPB (Oxford) 2006, 8:324-336.
59. Liu F. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2001, 7:4115-4121.
60. Clin. Cancer Res. 2001, 7:3853-3856.
61. Cascinu S., Falconi M., Valentini V., Jelic S. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21(Suppl. 5):v55-58.
62. Scully R., Livingston D.M. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000, 408:429-432.
63. Somyajit K., Subramanya S., Nagaraju G. RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis 2010, 31:2031-2038.
64. Kennedy R.D., D'Andrea A.D. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005, 19:2925-2940.
65. Joenje H., Patel K.J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet. 2001, 2:446-457.
66. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171-182.
67. Shammas M.A., Shmookler Reis R.J., Koley H., Batchu R.B., Li C., Munshi N.C. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 2009, 113:2290-2297.
68. Pal J., Bertheau R., Buon L., Qazi A., Batchu R.B., Bandyopadhyay S., Ali-Fehmi R., Beer D.G., Weaver D.W., Reis R.S., Goyal R.K., Huang Q., Munshi N.C., Shammas M.A. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. Oncogene 2011, doi:10.1038/onc.2011.83.
69. Richardson C., Stark J.M., Ommundsen M., Jasin M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004, 23:546-553.
70. Francis R., Richardson C. Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements. Genes Dev 2007, 21:1064-1074.
71. Hamada S., Shimosegawa T. Biomarkers of pancreatic cancer. Pancreatology 2011, 11(Suppl. 2):14-19.
72. Brand R.E., Nolen B.M., Zeh H.J., Allen P.J., Eloubeidi M.A., Goldberg M., Elton E., Arnoletti J.P., Christein J.D., Vickers S.M., Langmead C.J., Landsittel D.P., Whitcomb D.C., Grizzle W.E., Lokshin A.E. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 2011, 17:805-816.
73. Goggins M. Markers of pancreatic cancer: working toward early detection. Clin. Cancer Res. 2011, 17:635-637.
74. Turner B.G., Cizginer S., Agarwal D., Yang J., Pitman M.B., Brugge W.R. Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracy. Gastrointest. Endosc. 2010, 71:91-98.
75. Zhang L., Xiao H., Karlan S., Zhou H., Gross J., Elashoff D., Akin D., Yan X., Chia D., Karlan B., Wong D.T. Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 2010, 5:e15573.
76. Qiao G.B., Wu Y.L., Yang X.N., Zhong W.Z., Xie D., Guan X.Y., Fischer D., Kolberg H.C., Kruger S., Stuerzbecher H.W. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 2005, 93:137-143.
77. Soderlund K., Skoog L., Fornander T., Askmalm M.S. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother. Oncol. 2007, 84:242-251.
78. Xie K., Wei D., Shi Q., Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev. 2004, 15:297-324.
79. Xie K., Huang S. Regulation of cancer metastasis by stress pathways. Clin. Exp. Metastasis 2003, 20:31-43.
80. Bello V.E., Aloyz R.S., Christodoulopoulos G., Panasci L.C. Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem. Pharmacol. 2002, 63:1585-1588.
81. Slupianek A., Hoser G., Majsterek I., Bronisz A., Malecki M., Blasiak J., Fishel R., Skorski T. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol. Cell. Biol. 2002, 22:4189-4201.
82. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., Sarkar F.H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:27-33.
83. Vispe S., Cazaux C., Lesca C., Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 1998, 26:2859-2864.
84. Collis S.J., Tighe A., Scott S.D., Roberts S.A., Hendry J.H., Margison G.P. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001, 29:1534-1538.
85. Tsai M.S., Kuo Y.H., Chiu Y.F., Su Y.C., Lin Y.W. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J. Pharmacol. Exp. Ther. 2010, 335:830-840.
86. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
87. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell. 2008, 14:818-829.
88. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006, 7:131-142.
89. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
90. Sabbah M., Emami S., Redeuilh G., Julien S., Prevost G., Zimber A., Ouelaa R., Bracke M., De Wever O., Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11:123-151.
91. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31:277-283.
92. Konecny G.E., Venkatesan N., Yang G., Dering J., Ginther C., Finn R., Rahmeh M., Fejzo M.S., Toft D., Jiang S.W., Slamon D.J., Podratz K.C. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer 2008, 98:1076-1084.
93. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
94. Yang A.D., Fan F., Camp E.R., van Buren G., Liu W., Somcio R., Gray M.J., Cheng H., Hoff P.M., Ellis L.M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12:4147-4153.
95. Nagaraj N.S., Smith J.J., Revetta F., Washington M.K., Merchant N.B. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol. Cancer Ther. 2010, 9:2322-2332.
96. Nagaraj N.S., Washington M.K., Merchant N.B. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin. Cancer Res. 2011, 17:483-493.
97. Tang C., Ang B.T., Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J. 2007, 21:3777-3785.
98. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
99. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
100. Williams S.D., Birch R., Einhorn L.H., Irwin L., Greco F.A., Loehrer P.J. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 1987, 316:1435-1440.
101. Styczynski J., Drewa T. Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim. Pol. 2007, 54:717-726.
102. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
103. Croker A.K., Allan A.L. Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell. Mol. Med. 2008, 12:374-390.
104. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006, 66:1883-1890. discussion 1895-1886.
105. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., Melton D.A. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002, 298:597-600.
106. Ivanova N.B., Dimos J.T., Schaniel C., Hackney J.A., Moore K.A., Lemischka I.R. A stem cell molecular signature. Science 2002, 298:601-604.
107. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 2010, 13:57-66.
108. Croce C.M., Calin G.A. miRNAs, cancer, and stem cell division. Cell 2005, 122:6-7.
109. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
110. Rui W., Bing F., Hai-Zhu S., Wei D., Long-Bang C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells. J. Cell. Mol. Med. 2010, 14:206-214.
111. Song B., Wang Y., Xi Y., Kudo K., Bruheim S., Botchkina G.I., Gavin E., Wan Y., Formentini A., Kornmann M., Fodstad O., Ju J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
112. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
113. Wang Z., Li Y., Ahmad A., Azmi A.S., Kong D., Banerjee S., Sarkar F.H. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist. Updat. 2010, 13:109-118.
114. Garofalo M., Croce C.M. microRNAs: master regulators as potential therapeutics in cancer. Annu. Rev. Pharmacol. Toxicol. 2011, 51:25-43.
115. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., Enzo E., Guzzardo V., Rondina M., Spruce T., Parenti A.R., Daidone M.G., Bicciato S., Piccolo S. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
116. Huang J.W., Villegas E., Taniguchi T. MicroRNA-mediated regulation of the Fanconi anemia-BRCA pathway. American Association for Cancer Research 101st Annual Meeting, Washington, DC 2010, 1951.
117. Farrell J.J., Elsaleh H., Garcia M., Lai R., Ammar A., Regine W.F., Abrams R., Benson A.B., Macdonald J., Cass C.E., Dicker A.P., Mackey J.R. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136:187-195.
118. Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., Alberts S., O'Dwyer P., Haller D., Catalano P., Cella D., Benson A.B. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2009, 27:3778-3785.
119. Kindler H.L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M.F., O'Reilly E., Wozniak T.F., Picus J., Bhargava P., Mayer R.J., Schilsky R.L., Goldberg R.M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B. J. Clin. Oncol. 2010, 28:3617-3622.
120. Philip P.A., Benedetti J., Corless C.L., Wong R., O'Reilly E.M., Flynn P.J., Rowland K.M., Atkins J.N., Mirtsching B.C., Rivkin S.E., Khorana A.A., Goldman B., Fenoglio-Preiser C.M., Abbruzzese J.L., Blanke C.D. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 2010, 28:3605-3610.
121. Tempero M.A., Berlin J., Ducreux M., Haller D., Harper P., Khayat D., Schmoll H.J., Sobrero A., Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann. Oncol. 2011.
122. Van Cutsem E., Vervenne W.L., Bennouna J., Humblet Y., Gill S., Van Laethem J.L., Verslype C., Scheithauer W., Shang A., Cosaert J., Moore M.J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 2009, 27:2231-2237.
123. Taki T., Ohnishi T., Yamamoto A., Hiraga S., Arita N., Izumoto S., Hayakawa T., Morita T. Antisense inhibition of the RAD51 enhances radiosensitivity. Biochem. Biophys. Res. Commun. 1996, 223:434-438.
124. Ohnishi T., Taki T., Hiraga S., Arita N., Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem. Biophys. Res. Commun. 1998, 245:319-324.
125. Sak A., Stueben G., Groneberg M., Bocker W., Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br. J. Cancer 2005, 92:1089-1097.
126. Russell J.S., Brady K., Burgan W.E., Cerra M.A., Oswald K.A., Camphausen K., Tofilon P.J. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 2003, 63:7377-7383.
127. Ito M., Yamamoto S., Nimura K., Hiraoka K., Tamai K., Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J. Gene Med. 2005, 7:1044-1052.
128. Hannay J.A., Liu J., Zhu Q.S., Bolshakov S.V., Li L., Pisters P.W., Lazar A.J., Yu D., Pollock R.E., Lev D. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 2007, 6:1650-1660.
129. Koch K., Wrona A., Dikomey E., Borgmann K. Impact of homologous recombination on individual cellular radiosensitivity. Radiother. Oncol. 2009, 90:265-272.
130. Hine C.M., Seluanov A., Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20810-20815.
131. Arias-Lopez C., Lazaro-Trueba I., Kerr P., Lord C.J., Dexter T., Iravani M., Ashworth A., Silva A. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 2006, 7:219-224.
132. Lazaro-Trueba I., Arias C., Silva A. Double bolt regulation of Rad51 by p53: a role for transcriptional repression. Cell Cycle 2006, 5:1062-1065.
133. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
134. Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E., Stambrook P.J. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008, 27:3977-3985.
135. Thorslund T., West S.C. BRCA2: a universal recombinase regulator. Oncogene 2007, 26:7720-7730.
136. Gudmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864-5874.